HLS Therapeutics Inc.
HLS Therapeutics Inc. (HLTRF) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
hltrf · stock forecast · 1 analysts (3M) · FMP · updated Jun 9, 2026
Analyst Rating & Consensus
Based on 1 Wall Street analysts in the past 3 months
Hold
1 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $3.15
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $3.10 | ↓ 1.73% |
1-day model range: $3.09–$3.1. Peak: $3.1 (-1.73%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $2 | -26.2% |
| 2028 | $2 | -35.9% |
| 2029 | $2 | -40.1% |
| 2030 | $2 | -42.1% |
| 2031 | — | -43.0% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · HLTRF · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2024-03-18 | Raymond James | Maintains | Market Perform→Market Perform |
| 2021-08-06 | Raymond James | Downgrade ↓ | Outperform→Market Perform |
Wall Street analysts have recently issued updated ratings on HLS Therapeutics Inc. (HLTRF) stock. Of the recent 2 rating actions, 0 were upgrades and 1 were downgrades. 1 analysts currently cover HLTRF.
Analyst Recommendation Trends
HLTRF analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 0 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$58M
↓ 24.8% YoY
Revenue Next Year
$64M
↑ 10.8% YoY
EPS This Year
$-0.27
EPS Next Year
$-0.03
↓ 88.9% YoY
EPS ForecastReported vs Estimated
Analysts forecast HLTRF EPS of $-0.27 for the current fiscal year, based on estimates from 1 analysts. The HLTRF revenue forecast is $58M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The HLTRF stock forecast is supported by two independent data sources: analyst consensus ratings from 1 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus HLTRF price target is $0.00 (+0.0% upside), with an analyst consensus of Hold.
The HLTRF short-term stock prediction for tomorrow is $3.10 (-1.73%). The HLTRF stock price prediction for 2027 estimates an average of $2. The HLTRF stock prediction for 2030 projects a range of $2–$2.
HLS Therapeutics Inc. trades on OTC under the ticker HLTRF. The HLTRF stock outlook for 2027 is broadly mixed, supported by a Hold consensus among 0% of covering analysts.
Frequently asked questions
HLTRF forecast · 8 questionsAccording to 1 Wall Street analysts, the average 12-month HLTRF price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $3.15.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.